Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index
ConclusionsIgG4-RI is a promising outcome measure in IgG4-RD, but still in development. Treatment algorithms are ill defined. GC and rituximab are the drugs with more evidence available. Disease modifying anti-rheumatic drugs may have a role in IgG4-RD and warrant more prospective studies.
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
More News: Autoimmune Disease | Internal Medicine | Pathology | Rheumatology | Rituxan | Spain Health | Study